These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 29972607

  • 21. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
    Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM.
    Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
    [Abstract] [Full Text] [Related]

  • 22. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
    Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.
    Mol Cancer Ther; 2018 Feb; 17(2):554-564. PubMed ID: 29142066
    [Abstract] [Full Text] [Related]

  • 23. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.
    Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
    [Abstract] [Full Text] [Related]

  • 24. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.
    Majeti R.
    Oncogene; 2011 Mar 03; 30(9):1009-19. PubMed ID: 21076471
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
    Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N.
    Haematologica; 2018 Aug 03; 103(8):1288-1297. PubMed ID: 29773600
    [Abstract] [Full Text] [Related]

  • 27. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells.
    Stein C, Kellner C, Kügler M, Reiff N, Mentz K, Schwenkert M, Stockmeyer B, Mackensen A, Fey GH.
    Br J Haematol; 2010 Mar 03; 148(6):879-89. PubMed ID: 20064159
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
    He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, Marlton P, McLachlan AJ, Kerridge I, Bradstock KF, Kennedy G, Boyd AW, Yeadon TM, Lopez AF, Ramshaw HS, Iland H, Bamford S, Barnden M, DeWitte M, Basser R, Roberts AW.
    Leuk Lymphoma; 2015 May 03; 56(5):1406-15. PubMed ID: 25248882
    [Abstract] [Full Text] [Related]

  • 32. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.
    Mardiros A, Forman SJ, Budde LE.
    Curr Opin Hematol; 2015 Nov 03; 22(6):484-8. PubMed ID: 26457961
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.
    Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, Jordan CT, Dong Y.
    Bioorg Med Chem; 2016 Nov 15; 24(22):5855-5860. PubMed ID: 27687970
    [Abstract] [Full Text] [Related]

  • 36. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
    Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, Bai C, Rui L, Laleau R, Liu F, Ab O, Setiady Y, Yoder NC, Goldmacher VS, Chari RVJ, Pinkas J, Chittenden T.
    Blood Adv; 2018 Apr 24; 2(8):848-858. PubMed ID: 29661755
    [Abstract] [Full Text] [Related]

  • 37. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
    Andreasen RB, Olsson L.
    J Immunol; 1986 Aug 01; 137(3):1083-90. PubMed ID: 3459756
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.
    Zhang Y, Park M, Ghoda LY, Zhao D, Valerio M, Nafie E, Gonzalez A, Ly K, Parcutela B, Choi H, Gong X, Chen F, Harada K, Chen Z, Nguyen LXT, Pichiorri F, Chen J, Song J, Forman SJ, Amanam I, Zhang B, Jin J, Williams JC, Marcucci G.
    J Hematol Oncol; 2024 Aug 14; 17(1):67. PubMed ID: 39143574
    [Abstract] [Full Text] [Related]

  • 40. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A, Pinto AD, Al-Zadjali S.
    Acta Haematol; 2017 Aug 14; 138(3):175-181. PubMed ID: 29065396
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.